Research-Grade peptide Products

A small-molecule NNMT inhibitor (technically not a peptide) grouped with peptides in fat-loss contexts, investigated in preclinical obesity and muscle-aging models.

A 16-amino-acid fragment of the C-terminus of human growth hormone (residues 176–191), marketed for fat-loss lipolytic activity but weak in controlled human trials.

A 15-amino-acid peptide fragment derived from gastric juice protein BPC, studied extensively in animal models for tissue healing and gut integrity.

The most widely used GHRH + GHRP stack — CJC-1295 extends GHRH half-life while Ipamorelin selectively amplifies GH pulses without disturbing cortisol or prolactin.

A 9-amino-acid neuropeptide isolated from the rabbit brain, investigated for delta-wave sleep promotion and stress-axis modulation.

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on pineal extract Epithalamin — studied by Russian researchers for telomerase, circadian, and longevity endpoints.

An early-generation growth-hormone-releasing peptide with potent GHSR agonism but notable prolactin elevation compared to the later selective agent Ipamorelin.

The first-generation growth-hormone-releasing peptide, notable for inducing strong hunger through ghrelin-receptor activation alongside GH release.

A potent GHRP with documented cardioprotective effects in ischemic animal models, distinct from other GHRPs in its non-GH receptor activity.

A long-acting analog of insulin-like growth factor 1 with substitutions that reduce IGF-binding-protein affinity, extending half-life and increasing free IGF-1 activity.

The most selective GHRP (growth-hormone-releasing peptide) — amplifies GH pulses via ghrelin/GHSR receptor without meaningful cortisol, prolactin, or aldosterone crosstalk.

A synthetic analog of α-MSH that binds melanocortin receptors, inducing melanogenesis (tanning) along with libido and appetite-suppression effects. Pre-PT-141 ancestor molecule.

A 16-amino-acid peptide encoded in the mitochondrial 12S rRNA — investigated as a metabolic regulator of AMPK signaling and insulin sensitivity.

A synthetic heptapeptide analog of tuftsin, developed at the Russian Institute of Molecular Genetics as an anxiolytic nootropic administered intranasally.

A synthetic heptapeptide fragment of ACTH (4-10) developed in Russia as a cognitive enhancer, used clinically there for stroke recovery and anxiety.

The first synthetic GHRH analog approved for clinical use — GHRH (1-29) NH₂, the minimum active sequence. Shorter-acting than tesamorelin or CJC-1295.

Synthetic fragment of Thymosin β4 investigated for actin-binding, cell migration, and tissue repair across muscle, cornea, and cardiac models.